Related Experiment Video
Updated: Jun 12, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in
Rong-Rong Jing1, Ming Cui, Bao-Lan Sun
1Center of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People's Republic of China.
Abstract:
The receptor for advanced glycation end products (RAGE) interacts with several ligands and is involved in various human diseases. Several splicing forms of the RAGE gene have been characterized, and two general mechanisms are usually responsible for the generation of soluble receptors. However, variants distribution and respective roles in different tumors are not clear. We analyzed RAGE and hRAGEsec mRNA expression in esophageal and lung cancer by RT-polymerase chain reaction. The Agilent clipper 1000 Bioanalyzer using lab-on-a-chip technology was applied to size and quantify the polymerase chain reaction products. Western blotting was performed to measure total soluble RAGE protein levels. The results showed that RAGE and its splice variants increased in esophageal cancers and decreased in lung cancers. We conclude that RAGE presents as a major isoform; soluble RAGE may also play certain roles in esophageal cancer and lung cancer.
Insights
The receptor for advanced glycation end products (RAGE) and its splice variants show distinct expression patterns in esophageal and lung cancers. RAGE levels increased in esophageal tumors but decreased in lung tumors, suggesting varied roles in cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The receptor for advanced glycation end products (RAGE) is implicated in numerous human diseases.
- Splicing variants of RAGE exist, leading to soluble forms, but their distribution and roles in tumors are unclear.
Purpose of the Study:
- To investigate the expression of RAGE and its splice variants in esophageal and lung cancers.
- To determine the levels of soluble RAGE protein in these cancer types.
Main Methods:
- RT-polymerase chain reaction (RT-PCR) was used to analyze RAGE and hRAGEsec mRNA expression.
- Agilent clipper 1000 Bioanalyzer with lab-on-a-chip technology quantified PCR products.
- Western blotting measured total soluble RAGE protein levels.
Main Results:
- RAGE and its splice variants showed increased expression in esophageal cancers.
- RAGE and its splice variants showed decreased expression in lung cancers.
- Soluble RAGE protein levels were measured, indicating differential expression patterns.
Conclusions:
- RAGE is a major isoform in these cancers.
- Soluble RAGE may play distinct roles in the pathogenesis of esophageal and lung cancers.
More Related Videos
12:16Production, Characterization and Potential Uses of a 3D Tissue-engineered Human Esophageal Mucosal Model
Published on: May 18, 2015
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016